mRNA-1273 vaccine also tied to greater protection against COVID-19 in older adults
Bell Palsy Incidence Higher With SARS-CoV-2 Infection Than Vaccine
However, review showed significantly increased incidence of Bell palsy in vaccine recipients versus those receiving placebo
Adverse Events Detailed for Teen COVID-19 Vaccination Program
Overall, 17.7 cases of myocarditis reported per million vaccinations; 77 percent had symptom resolution at time of report
Axillary Lymphadenopathy Resolves at Mean 102 Days After COVID-19 Booster
No significant associations seen for age, vaccine booster type, history of breast cancer with time to resolution
Adverse Reactions to BNT162b2 Mild, Moderate for 5- to 11-Year-Olds
Based on data from three U.S. safety monitoring systems, adverse events were mild-to-moderate, and myocarditis occurred rarely
Veterans Report Low Rates of Adverse Events With mRNA Vaccines
Rates slightly higher at 42 days for those receiving Pfizer versus Moderna
One in Nine May Get Delayed Large Local Reaction After Moderna Vaccine
Higher risk seen among women and among individuals aged 30 to 69 years
Risk for Guillain-Barré Syndrome Up After Ad.26.COV2.S Vaccination
Adjusted rate ratio of 20.56 found in head-to-head comparison of Ad.26.COV2.S with mRNA COVID-19 vaccines
Drug Interaction Checkers Could Have Caught Adverse Events
More than three-quarters of COVID-19-associated drug-drug interactions could have been identified
Survivors of Severe COVID-19 Report Many Long-Term Symptoms
Findings show physical, mental, and cognitive symptoms one year after ICU stay for COVID-19